Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed this Current Report on Form 8-K on August 24, 2026. The filing discloses a significant clinical development milestone for the company's gene therapy program targeting Duchenne muscular dystrophy (DMD).
Key Financial Metrics
This filing is a non-financial event report. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Clinical Milestone
- Clinical Trial Update: The Company announced that the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial.
- Therapeutic Candidate: The trial evaluates PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).
- Location: The dosing occurred at Arkansas Children's Hospital.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard regulatory disclosure. The information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed trial design and safety monitoring plans.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial data.
- Monitor future 8-K filings for safety data readouts or enrollment updates from the FUNCTION-DMD trial.